AVANIR PHARMACEUTICALS (AVNR)

[sts66]

"There must be a BIG NEED for NEUDEXTA because otherwise what fool would bring a generic version of it on the market. As momentarily only one in it's kind for at least 30 next months that is good news for Avanir. Isn't it ?"

It would certainly appear that way....even those louts at Jefferies with their <spit> $3.50 price target found it rather interesting that the ANDA was filed so quickly:

Jefferies & Co. has a Hold rating and a $3.50 price target on shares of Avanir Pharmaceuticals (NASDAQ: AVNR).

In the note, Jefferies writes, "Notice of a Paragraph IV certification challenging AVNR's Nuedexta appeared on the FDA website on 6/30. While we had been anticipating a Paragraph IV challenge, we think the submission date of 3/7 was notable, since AVNR only officially began promoting Nuedexta on 2/7, following its approval on 10/29."



Read more: http://www.benzinga.com/analyst-ratings/analyst-color/11/07/1221658/jefferies-has-hold-on-avanir-pharmaceuticals#ixzz1QsYpyNCV